Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/301% above fair value
$69.00−0.84 (-1.20%)
Close on Nov 13, 2026Market cap $16.84BP/E 20.7Yield –
Exelixis EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Exelixis's EV/EBITDA was 16.8× on Nov 11, 2026, against 13.1× a year earlier. Over the last 5 years it ranged from 9.5× to 96.1×, with a median of 15.7×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 16.8× | +3.8 |
| 2025 | Dec 31, 2025 | 13.0× | −2.1 |
| 2024 | Dec 31, 2024 | 15.1× | −81.0 |
| 2023 | Dec 29, 2023 | 96.1× | +86.6 |
| 2022 | Dec 30, 2022 | 9.5× | −11.4 |
| 2021 | Dec 31, 2021 | 20.9× | −8.3 |
| 2020 | Dec 31, 2020 | 29.2× | +18.0 |
| 2019 | Dec 31, 2019 | 11.1× | −3.1 |
| 2018 | Dec 31, 2018 | 14.3× | −36.9 |
| 2017 | Dec 29, 2017 | 51.2× | +44.1 |
| 2012 | Oct 31, 2012 | 7.1× | – |
See a number that looks wrong?